Investigation of the cytokine response to NF-κB decoy oligonucleotide coated polysaccharide based nanoparticles in rheumatoid arthritis  models by unknown
Investigation of the cytokine response to
NF-κB decoy oligonucleotide coated
polysaccharide based nanoparticles in
rheumatoid arthritis in vitro models
Wardwell et al.
Wardwell et al. Arthritis Research & Therapy  (2015) 17:310 
DOI 10.1186/s13075-015-0824-x
RESEARCH ARTICLE Open Access
Investigation of the cytokine response to
NF-κB decoy oligonucleotide coated
polysaccharide based nanoparticles in
rheumatoid arthritis in vitro models
Patricia R. Wardwell1,2*, Martin B. Forstner1,3 and Rebecca A. Bader1,2
Abstract
Introduction: The transcription factor nuclear factor-kappa B (NF-κB) is highly involved in regulation of a number of
cellular processes, including production of inflammatory mediators. Thus, this transcription factor plays a role in
pathology of many diseases, including rheumatoid arthritis, an autoimmune disease hallmarked by an imbalance
of pro and anti-inflammatory cytokines. Small nucleic acids with sequences that mimic the native binding site of
NF-κB have been proposed as treatment options for RA; however due to low cellular penetration and a high
degree of instability, clinical applications of these therapeutics have been limited.
Methods: Here, we describe the use of N-trimethyl chitosan-polysialic acid (PSA-TMC) nanoparticles coated with
decoy oligodeoxynucleotides (ODNs) specific to transcription factor NF-κB (PSA-TMC-ODN) as a method to enhance
the stability of the nucleic acids and facilitate increased cellular penetration. In addition to decoy ODN, PSA-TMC
nanoparticles were loaded with RA therapeutic methotrexate (MTX), to assess the anti-inflammatory efficacy of a
combination therapy approach. Two different in vitro models, a cell line based model as well as a primary RA cell
model were used to investigate anti-inflammatory activity. One way ANOVA followed by Holm-Sidak stepdown
comparisons was used to determine statistical significance.
Results: In general, free ODN did not significantly affect secretion of pro-inflammatory cytokines interleukin-6 (IL-6)
and interleukin-8, (IL-8) while free MTX had variable efficacy. However, PSA-TMC-ODN and PSA-TMC-ODN-MTX
resulted in significant decreases in the inflammatory mediators IL-6 and IL-8 in both cell models. In addition,
PSA-TMC exhibited sufficient cellular uptake, as observed through fluorescence microscopy.
Conclusions: These results support our previous findings that PSA-TMC nanoparticles are an effective delivery
vehicle for small nucleic acids, and effectively alter the pro-inflammatory state characteristic of RA.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease
characterized by inflammation of the synovial tissue of
joints. Over time, the infiltration of immune cells to the
synovial lining leads to hyperplasia, increased vascular
growth, and formation of a tumor-like tissue known as
the pannus [1]. The physiology of a chronic inflammatory
state eventually results in cartilage degradation and bone
resorption. An imbalance of proinflammatory and anti-
inflammatory cytokines contributes to the state of chronic
inflammation. Briefly, the levels of anti-inflammatory cyto-
kines (interleukin (IL)-4, IL-10, and IL-13) present in the
synovium are too low to combat the effects of proin-
flammatory cytokines (tissue necrosis factor alpha (TNFα),
IL-1, IL-6, and IL-8) [2]. Of the cells present in the RA syn-
ovial lining, “macrophage-like” cells and activated synovial
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fibroblasts are accepted as the primary mediators of the
proinflammatory/anti-inflammatory imbalance [3, 4].
Nuclear factor kappa-light chain enhancer of activated
B cells (NF-κB) is a transcription factor involved in the
regulation of a variety of cellular processes, including
growth, apoptosis, and inflammatory and immune re-
sponses [5]. NF-κB-dependent gene expression is known
to play a critical role in the observed cytokine imbalance,
as well as to contribute to increased inflammation in RA
[6, 7]. Under normal conditions, NF-κB is sequestered in
the cytoplasm by means of a bound inhibitor known as
inhibitor of NF-κB (IκB). External stimulation from in-
flammatory mediators, including IL-1β, leads to a signal-
ing cascade that results in phosphorylation of the
inhibitor, followed by dissociation of the NF-κB/IκB
complex and subsequent nuclear translocation of NF-κB.
Once inside the nucleus, NF-κB initiates transcription of
proinflammatory cytokines, including IL-6 and IL-8, two
cytokines highly involved in regulating inflammation in
RA. IL-6 and IL-8 both possess NF-κB binding sites on
their promotor regions, indicating they are highly
regulated by NF-κB [8]. Transcription factor decoy
oligonucleotides (ODNs) have the potential to reduce in-
flammation in RA by binding to NF-κB in the cytoplasm,
preventing nuclear translocation, and mitigating tran-
scription of proinflammatory proteins. The mechanism
of decoy ODN is illustrated in Fig. 1.
Transcription factor decoy ODNs mimic the native
DNA binding site of the transcription factor, but are
only ~20 base pairs long and do not encode any genes.
NF-κB decoy ODNs are desirable drug candidate be-
cause they provide a way to selectively regulate specific
genes [9]. A number of reviews herald decoy ODNs as a
potential future treatment for a variety of pathologies,
including inflammatory and autoimmune disorders, such
as RA [9–12]. However, despite promising potential for
treatment, applications have been limited by low cellular
penetration and a lack of stability of the nucleotides, which
combined result in low overall bioavailability [13, 14]. To
overcome stability problems, chemical modifications such
as phosphorothioate or methyl phosphonate are often
applied to the nucleotide backbones [15]. While these
modifications enhance stability, they do not necessarily
lead to increased delivery efficiency, resulting in the need
for a high dose and frequently repeated delivery. This is
not a sustainable method for delivery, as phosphorothioate
nucleic acids have been shown to have a concentration-
dependent toxicity [16, 17].
Methods such as viral vectors, cationic lipid formula-
tions, and, more recently, cationic polymer formulations
exist to overcome the barriers to nucleic acid delivery. In
general, drug delivery systems for nucleic acids must have
the following attributes: biocompatibility and biodegrad-
ability, reticuloendothelial system (RES) avoidance, non-
immunogenicity, cellular uptake capability, and cell or
tissue specificity [18]. Viral vectors are associated with
major drawbacks, including viral-induced immunogen-
icity, toxicity, mutation of the nucleic acid of interest with
the viral DNA, and the potential for inactivation of the
gene of interest due to recombination [19]. Lipofectamine
reagents, marketed by Life Technologies (Carlsbad, CA,
USA), have become the most referenced cationic lipid-
based transfection reagent, with the claim of increased ef-
ficiency over other available reagents. However, these
compounds often exhibit cytotoxicity and are prone to
accumulation within the liver in vivo, leading to significant
nucleic acid payload degradation [20, 21]. Recent research
has focused on the alternative use of cationic polymers for
nucleic acid delivery. Poly(ethyleneimine) (PEI) is one of
the most widely used cationic polymers for nucleic acid
delivery; however, PEI exhibits considerable toxicity to-
ward a variety of mammalian cells [22, 23]. Delivery sys-
tems for RA, where the ultimate goal is to reduce
inflammation, require materials that do not contribute to
inflammation or the immune response and that exhibit
low levels of toxicity. Therefore, an alternative delivery
method to viral vectors, cationic lipids, and synthetic cat-
ionic polymers is needed.
We have recently described a nanoparticle system
based on two natural polymers, N-trimethyl chitosan
(TMC) and polysialic acid (PSA). This nanoparticle
Fig. 1 NF-κB pathway activation in a RA synovial fibroblast cell.
Proinflammatory cytokines, including IL-1β, activate the cell
signaling pathway associated with NF-κB, including activation of
IκK, phosphorylation and inactivation of Iκβ, and translocation of
NF-κB to the nucleus. NF-κB decoy ODNs can prevent translocation
of the transcription factor, as well as subsequent transcription of
NF-κB-dependent genes. IκB inhibitor of NF-κB, IL interleukin, NF-κB
nuclear factor kappa-light chain enhancer of activated B cells
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system is noncytotoxic, is nonimmunogenic, and has been
shown to effectively deliver encapsulated disease-modifying
anti-rheumatic drugs (DMARDs) and surface-coated NF-
κB decoy ODNs when applied to in vitro models of RA and
cystic fibrosis (CF), respectively [24, 25]. In this manu-
script, we report the use of PSA–TMC nanoparticles
(NP) as a delivery system to combine treatment of a
DMARD, methotrexate (MTX), and NF-κB decoy ODN.
Methods
Materials
PSA (colominic acid) was obtained from Nacalai USA,
Inc. (San Diego, CA, USA). TMC was produced via qua-
ternization of chitosan (molecular weight 100–300 Da)
obtained from Acros Organics (Morris, NJ, USA), as de-
scribed previously by Sieval et al. [26]. Sodium tripoly-
phosphate (TPP) was purchased from Acros Organics.
An NF-κB decoy ODN kit containing NF-κB decoy
ODN (5′-CCT TGA AGG GAT TCC CTT CC-3′) and
a scrambled ODN (SCO; 5′-TTG CCG TAC CTG ACT
TAG CC-3′) was purchased from CosmoBio (Tokyo,
Japan). Recombinant human IL-1β was obtained from R
& D systems (Minneapolis, MN, USA). MTX was pur-
chased from Enzo Life Sciences (Rochester, NY, USA).
Alexa Fluor 488 succinimidyl ester was purchased from
Invitrogen/Life Technologies (Grand Island, NY, USA).
Cell culture
SW982 cells were obtained from ATCC (Manassas, VA,
USA) and grown in Dulbecco’s modified Eagle’s medium
(DMEM; Fisher Scientific, Pittsburgh, PA, USA) supple-
mented with 10 % fetal bovine serum (FBS; Atlanta Bio-
logicals, Atlanta, GA, USA) until confluent. Primary RA
cells were isolated from synovial tissue obtained from
two Caucasian RA patients, both women between the
ages of 50 and 59. The use of human samples was ap-
proved by the Syracuse University Institutional Review
Board (IRB). The tissue samples were obtained by Dr
Timothy Damron at Community General Hospital (Syra-
cuse, NY, USA) following written and informed consent
by each patient, as required by an IRB-approved protocol.
Tissue was isolated following a protocol outlined by Zim-
merman et al. [27]. Briefly, the synovial tissue was minced
finely and incubated at 37 °C with 0.1 % Trypsin (Invitro-
gen, Carlsbad, CA, USA) in phosphate-buffered saline
(PBS) for 30 minutes. Tissue was then digested for 2 hours
in DMEM with 0.1 % Collagenase P. After digestion, tissue
was filtered through a 100 μM filter. The resultant solu-
tion was centrifuged, and the pelleted cells were resus-
pended in DMEM with 10 % FBS, placed in a T-75 flask,
and cultured at 37 °C with 5 % CO2. After three passages,
the cells were stained with CD44-FITCmAB (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) to confirm fibro-
blast cells. To supplement the two sets of primary cells
obtained through synovial tissue isolation, human fibro-
blast-like synoviocytes (HFLS; lot numbers 2884 and
2956, female Caucasian) were obtained from Cell Ap-
plications (San Diego, CA, USA) and cultured in
DMEM with 10 % FBS at 37 °C with 5 % CO2.
Nanoparticle preparation and characterization
ODN-coated NP were prepared as described previously
[25]. Briefly, 6.4 mg TMC (55 % quaternization) were
dissolved in 3.0 ml of 0.3 % acetic acid in a glass vial.
Meanwhile, 3.2 mg PSA and 1.0 mg TPP were dissolved
in 2.0 ml DI (Deionized) water. To prepare nanoparticles
loaded with MTX, 2.4 mg MTX were added to the aque-
ous PSA solution. The latter solution was sonicated for
10 minutes and then added drop-wise to the TMC solu-
tion with stirring. Stirring was continued at room
temperature for 20 minutes. At this time, 10 μg ODN
were added to the nanoparticle suspension. Stirring was
continued for an additional 10 minutes to ensure uni-
form electrostatic adhesion of ODN to the nanoparticle
surface, as well as complete dispersion. Upon comple-
tion of stirring, centrifugation at 3000 rpm for 15 mi-
nutes yielded a pellet of ODN-coated NP.
Nanoparticle size, zeta potential, and polydispersity
index were determined using a Malvern Zetasizer
NanoZS90 (Malvern Instruments, Malvern, UK). Follow-
ing centrifugation, nanoparticles were resuspended at a
concentration of 2 mg/ml in DI water and filtered through
a 0.45 μM syringe filter. Samples were loaded into cuvettes
or capillary cells for measurements at 25 °C.
Determination of MTX loading
High-performance liquid chromatography (HPLC) was
used to determine the amount of MTX loaded into
ODN-coated nanoparticles. After nanoparticles were
pelleted via centrifugation, supernatant samples were
saved and analyzed using a Prominence Ultrafast Liquid
Chromatography System (Shimadzu Instruments, Kyoto,
Japan). Samples were run using a 93:7 (v/v) mixture of
50 mM ammonium acetate and acetonitrile mobile
phase at a flow rate of 0.75 ml/minute with a 100 μl in-
jection volume. The detection wavelength used was
210 nm. To determine the amount of MTX present
based on peak area, a calibration curve of eight known
concentrations (from 50 to 0.39 μg/ml) of MTX was
constructed. PeakFit 4.2 (SYSTAT Software, San Jose,
CA, USA) software was used to analyze the peak area.
In vitro efficacy of ODN-coated NP
SW982 cells or primary RASF cells were plated on
24-well plates at a density of 20,000 cells/well. Nanoparti-
cles were prepared as described in Nanoparticle prepar-
ation and characterization. In addition to ODN-coated
nanoparticles (NP-ODN), bare nanoparticles (NP), MTX-
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loaded nanoparticles (NP-MTX), ODN-coated MTX-
loaded nanoparticles (NP-MTX-ODN), and nanoparticles
coated with a SCO (NP-SCO) were prepared. As a control,
MTX alone was prepared at a concentration of 1.0 mg/ml
DMEM media. After centrifugation, all nanoparticles were
resuspended in serum-free DMEM at a concentration of
1.0 mg/ml. Then 500 μl of each treatment group was
added to the 24-well plate in duplicate as follows: media
alone (control); ODN alone; NP-ODN; NP; NP-SCO; NP-
MTX; NP-ODN-MTX; and MTX alone. The complexes
were removed and media was replaced after 4 hours to
allow for normal growth conditions. The amount of ODN
in each treatment group was held constant at 1 μg/ml, or
approximately 500 ng/well. This concentration does not
have an impact on cellular proliferation. Twenty-four
hours after initial complex addition, inflammation was in-
duced with the addition of 1.0 ng/ml IL-1β. This concen-
tration has been shown to increase levels of IL-6 and IL-8
when administered to SW982 cells [28]. After incubation
at 37 °C for an additional 24 or 48 hours, supernatant
samples were collected and stored at –80 °C for analysis
of IL-6 and IL-8.
Quantitative analysis of inflammatory cytokines
Enzyme-linked immunosorbent assay (ELISA) kits for
IL-6 and IL-8 were purchased from Peprotech (Rocky
Hill, NJ, USA) and run according to the manufacturer’s
instructions. Samples were run in duplicate, and each
experiment was repeated independently at least three
times.
In vitro cellular uptake
To examine internalization of the nanoparticles, cellular
uptake experiments were performed. Prior to nanoparticle
synthesis, TMC was tagged with Alexa-Fluor 488 carbox-
ylic acid, succinimidyl ester, and mixed isomers in
dimethylsulfoxide (DMSO; 1 mg/ml) (Invitrogen, Grand
Island, NY, USA). Then 25 mg TMC were dissolved in
4 ml of 0.1 M sodium bicarbonate buffer (pH 8.3), 500 μl
AF 488 dye were added, and the solution was stirred for
1 hour at room temperature. Upon completion of stirring,
the resultant material was dialyzed for 48 hours against
water to ensure removal of unreacted dye. In addition, the
amount of TMC used has an excess of reactive amine
groups relative to amount of Alexa Fluor 488, and there-
fore the amount of unreacted dye was expected to be neg-
ligible. 1H-NMR confirmed dye conjugation. Cells were
plated on lysine-coated glass-bottom dishes (Mattek Corp,
Ashland, MA, USA) at a density of 100,000 cells per dish
2 days prior to scheduled imaging to allow for adherence
and confluence. ODN-coated NP were prepared using
Alexa Fluor 488 tagged TMC, and Texas Red tagged
ODN. On the day of imaging, sterile filtered NP, NP-
ODN, and ODN alone were administered to the plated
cells at a concentration of 1.0 mg/ml, 1.0 mg/ml, and
500 ng/ml, respectively. The concentrations used were
well below the concentrations associated with cytotoxicity
in order to avoid any changes in uptake due to activation
of a cellular inflammatory response. Complexes were in-
cubated with the cells for 45 minutes at 37 °C prior to re-
moval. The cells were washed three times with 1× PBS
and imaged using a Nikon Eclipse Ti (Nikon Metrology,
Brighton, MI, USA) inverted microscope.
Statistical analysis
IL-6 and IL-8 protein levels were expressed relative to
an untreated, stimulated control group, with all data pre-
sented as mean ± standard deviation (SD) for all groups
(n ≥3). One-way analysis of variance (ANOVA) followed
by Holm–Sidak testing for multiple comparisons was
performed to compare IL-6 and IL-8 protein secretion
following treatment and inflammatory stimulation. All
statistical tests were conducted with α = 0.05.
Results
Nanoparticle loading and characterization
Our laboratory previously reported the use of NP for ef-
fective delivery of conventional, small molecule thera-
peutics, such as MTX and dexamethasone, as well
nucleic acid-based therapeutics, particularly decoy ODN
[24, 29]. As expected based on these prior studies, NP
possessed a size of close to 100 nm (115 nm) and a posi-
tive zeta potential (37 mV), while NP-ODN nanoparti-
cles possessed a significantly larger size with a diameter
of 159 ± 15 nm and a decrease in surface charge to
23 mV [24, 25]. Furthermore, NP-ODN loaded with MTX
led to another slight size increase, insignificantly larger
than NP-ODN alone, with a diameter of 184 ± 5.6 nm
while maintaining a positive zeta potential of approxi-
mately 33 ± 6.5 mV. All nanoparticle formulations pos-
sessed size between 100 and 200 nm, favorable for evading
the RES in applications for drug delivery [30].
HPLC was performed to determine the amount of
MTX loaded within the NP-ODN-MTX. Loading cap-
acity and loading efficiency values of 0.20 mg MTX/mg
nanoparticle and 86.7 %, respectively, were obtained.
The high loading efficiency of MTX suggests that the
majority of the drug is encapsulated prior to addition of
ODN to the nanoparticle suspension, and therefore in-
teractions between ODN and MTX are limited.
Effect of ODN-loaded and MTX-loaded NP on IL-6 and IL-8
secretion in RA in vitro models
Previously, we have reported the use of a luciferase re-
porter assay to confirm that the reduction in inflamma-
tory protein levels was in fact occurring due to decoy
ODN interference with NF-κB [24]. In the current study,
to initially determine efficacy of NF-κB decoy ODN-
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loaded and MTX-loaded NP, the SW982 cell line was
used as a model of RA. The SW982 cell line has been
shown to mimic activated RA synovial fibroblast cells
with regards to the expression of inflammatory media-
tors, particularly when stimulated in 1 ng/ml IL-1β [31].
We have previously conducted cytotoxicity studies of
NP formulations and concluded that NP, as well as
NP-ODN, NP-MTX, and MTX alone, do not impact
cellular proliferation at low concentrations and are
therefore appropriate for this study [24, 25]. In addition to
results on cytotoxicity, we recently demonstrated that
NP-ODN are effective at reducing inflammation in an
in vitro model of CF [24].
To assess the bioactivity of NP coated with the NF-κB
decoy ODN and/or loaded with MTX, the secretion of
two potent inflammatory mediators, IL-6 and IL-8, by
SW982 cells was investigated. Both of these proinflam-
matory mediators are directly influenced by NF-κB and
play a major role in the inflammatory response in RA.
IL-6 is a multifunctional cytokine, with the ability to
regulate the immune response, inflammation, and he-
matopoiesis, and plays a crucial role in RA pathogenesis
[32]. IL-8 was chosen as a representative chemokine and
is responsible for recruiting immune cells to the syno-
vium and contributing to the tumor-like pannus tissue.
In addition, IL-8 is involved in upregulation of inflam-
mation via paracrine signaling mechanisms in the RA
synovium [33]. The mechanism of action of MTX in RA
treatment and inflammatory activity is currently unre-
solved; however, the drug is believed to interfere with
cell folate metabolism. Furthermore, several reports
suggest MTX acts on NF-κB as an inhibitor [34]. We
explored coadministration of NF-κB decoy ODN and
MTX to observe any potential synergistic activity. IL-6
and IL-8 levels were examined in response to treatment
with NP-ODN, NP-MTX, NP-ODN-MTX, ODN alone,
and MTX alone using immunoassays.
The IL-6 secretion profile in response to different
treatment groups is shown in Fig. 2. In general, we were
interested in the IL-6 response of cells subjected to the
different treatment groups in comparison with untreated
control cells and in comparison with cells treated with
ODN alone. At 24 hours (Fig. 2a), cells treated with
NP-ODN-MTX displayed a significant reduction of
IL-6 relative to untreated control cells. A decrease in
IL-6 levels in comparison with untreated control cells
was also observed following treatment with NP-ODN;
however, this reduction was not great enough to be signifi-
cant. At 48 hours (Fig. 2b), a significant decrease relative
to both untreated control cells and cells administered
ODN alone was observed following treatment with NP-
MTX and NP-ODN-MTX. NP-ODN displayed trends at
48 hours similar to those at 24 hours. This treatment re-
sulted in a decrease in IL-6 levels in comparison with both
untreated control cells and ODN alone; however, the de-
crease was not great enough to be significantly different.
The IL-8 secretion profile from SW982 cells in re-
sponse to treatment with different nanoparticle for-
mulations is portrayed in Fig. 3. After 24 hours (Fig. 3a),
NP-ODN-MTX resulted in a significant decrease in IL-8
levels compared with ODN administered alone. While
the level of IL-8 in response to NP-ODN-MTX treat-
ment was lower than the untreated control, the differ-
ence was not significant. At 48 hours (Fig. 3b), multiple
significant decreases in IL-8 levels were observed. Cells
treated with NP-ODN, NP-MTX, NP-ODN-MTX, and
MTX alone all had IL-8 levels significantly lower than
the untreated control cells and cells treated with ODN
alone.
These results suggest that NP can be used to deliver
decoy ODN and MTX, alone and simultaneously, to ac-
tivated RA synovial fibroblasts. To further validate the
ability of NP to serve as an effective treatment strategy
for RA, in vitro experiments were also conducted with
Fig. 2 ELISA was performed to determine levels of IL-6 secretion by SW982 cell line RA model cells, after treatment with ODN alone, NP-ODN,
NP-MTX, NP-ODN-MTX, and MTX alone, and stimulation with IL-1β at (a) 24 hours and (b) 48 hours. Results are expressed as fold changes of IL-6
levels relative to an untreated control (solid line at 1). One-way ANOVA followed by Holm–Sidak multiple comparisons testing was used to determine
the impact of treatment on IL-6 secretion. *Significant difference from the control. †Significant difference from ODN alone. Data presented
as mean ± SD (n = 3). IL interleukin, MTX methotrexate, NP PSA-TMC nanoparticles, ODN oligonucleotide
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primary cells. Previous reports have noted discrepancies
in cytokine production between cell line models and pri-
mary RASF cells [35]. Furthermore, a literature search
revealed that immortalized cells, such as SW982, consti-
tutively express the NF-κB pathway, indicating that they
may be more susceptible to NF-κB interference than
primary RASF cells [36].
Primary RASF cell cytokine secretion was investigated
following treatment with ODN, NP-ODN, NP-MTX,
NP-ODN-MTX, and MTX. At 24 hours (Fig. 4a), a sig-
nificant reduction in IL-6 secretion by the primary cells
was observed in response to NP-ODN and NP-ODN-
MTX in comparison with untreated control cells, as well
as cells administered ODN alone. While cells treated
with NP-MTX and MTX alone experienced a decrease
in levels of IL-6, the decrease was not great enough to
be considered significant. A lack of significant reduction
of IL-6 secretion in response the NP-MTX and MTX
alone is in accordance with several reports, described in
further detail in the Discussion, stating that MTX does
not have a direct effect on IL-6 levels in primary RASF
cells. At 48 hours (Fig. 4b) although trends similar to
those at 24 hours are seen with reductions in IL-6 levels
in response to NP-ODN, NP-MTX, and NP-ODN-MTX,
significant reductions were not observed in response to
any NP treatment.
The IL-8 secretion response of primary RA cells to NP
treatments is depicted in Fig. 5. At 24 hours (Fig. 5a),
despite similar reduction trends to those observed for
primary IL-6 secretion and SW982 IL-8 secretion, the
differences were not significant. At 48 hours (Fig. 5b),
NP-ODN, NP-MTX, NP-ODN-MTX, and MTX alone
all resulted in significant decreases in IL-8 secretion
when compared with the untreated control. Further-
more, NP-ODN-MTX treatment resulted in a significant
decrease when compared with ODN alone.
Fig. 3 ELISA was performed to determine levels of IL-8 secretion by SW982 cell line RA model cells, after treatment with ODN alone, NP-ODN,
NP-MTX, NP-ODN-MTX, and MTX alone, and stimulation with IL-1β at (a) 24 hours and (b) 48 hours. Results are expressed as fold changes of IL-8
levels relative to an untreated control (solid line at 1). One-way ANOVA followed by Holm–Sidak multiple comparisons testing was used to determine
the impact of treatment on IL-8 secretion. *Significant difference from the control. †Significant difference from ODN alone. Data presented
as mean ± SD (n = 3). IL interleukin, MTX methotrexate, NP PSA-TMC nanoparticles, ODN oligonucleotide
Fig. 4 ELISA was performed to determine levels of IL-6 secretion by primary RA synovial fibroblast cells, after treatment with ODN alone, NP-ODN,
NP-MTX, NP-ODN-MTX, and MTX alone, and stimulation with IL-1β at (a) 24 hours and (b) 48 hours. Results are expressed as fold changes of IL-6
levels relative to an untreated control (solid line at 1). One-way ANOVA followed by Holm–Sidak multiple comparisons testing was used
to determine the impact of treatment on IL-6 secretion. *Significant difference from the control. †Significant difference from ODN alone. Data presented
as mean ± SD (n= 4). IL interleukin, MTX methotrexate, NP PSA-TMC nanoparticles, ODN oligonucleotide
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Cellular uptake of NP-ODN
To facilitate visualization of carrier uptake and localization
of NP and NPDON in vitro, TMC was modified with a
green (Alexa Fluor 488) fluorescent tag, and ODN was
modified with red (Texas Red). Tagged NP, NP-ODN,
and ODN were incubated with SW982 cells at 37 °C
for 45 minutes, and visualized. A composite image from
the uptake experiments is shown in Fig. 6. NP-ODN dem-
onstrated cellular uptake of both NP and ODN, while
ODN alone did not appear to enter the cells.
Discussion
A major barrier in the advancement of nucleic acid ther-
apies to achieving clinical relevance is a general lack in
ability of the negatively charged nucleic acid to enter the
negatively charged cell membrane. A number of posi-
tively charged carrier systems and transfection reagents
have been explored to overcome this barrier; however,
many of these are associated with toxicity, immunogen-
icity, and/or are highly variable based on cell type [37].
The NP carrier system presented here has been found to
be noncytotoxic, while maintaining a positive surface
charge [24, 25, 38]. We expect that the positive surface
charge of the particles due to TMC facilitates interaction
with negatively charged cell membranes, increasing
ODN cellular uptake. Meanwhile, PSA has no known re-
ceptors in the body, making it an optimal choice for a
component, as this will probably allow for RES evasion
and reduce the likelihood of inducing an immune re-
sponse. Further, PSA has properties similar to polyethyl-
ene glycol (PEG), a polymer commonly used to extend
circulation time via incorporation into nanocarrier sys-
tems or protein conjugates [25, 39–41]. In sum, we have
reported herein a nanoparticle system based on natural
polysaccharides, which is anticipated to reduce im-
munogenicity and enhance hydrophilicity. An NF-κB
decoy ODN was chosen as the NA (Nucleid acid) drug
of choice for this study due to the known activity of
NF-κB in RA pathology.
Under normal conditions, NF-κB is bound to an
inhibitor in the cytoplasm. However, in response to an
inflammatory stimulus, the inhibitor undergoes phosphor-
ylation, leading to dissociation of the NF-κB/inhibitor
complex and subsequent nuclear translocation of the tran-
scription factor. For this study, we chose to quantify IL-6
and IL-8 as the representative cytokine and chemokine,
Fig. 5 ELISA was performed to determine levels of IL-8 secretion by primary RA synovial fibroblast cells, after treatment with ODN alone, NP-ODN,
NP-MTX, NP-ODN-MTX, and MTX alone, and stimulation with IL-1β at (a) 24 hours and (b) 48 hours. Results are expressed as fold changes of IL-8
levels relative to an untreated control (solid line at 1). One-way ANOVA followed by Holm–Sidak multiple comparisons testing was used to determine
the impact of treatment on IL-8 secretion. *Significant difference from the control. †Significant difference from ODN alone. Data presented
as mean ± SD (n = 4). IL interleukin, MTX methotrexate, NP PSA-TMC nanoparticles, ODN oligonucleotide
Fig. 6 Cellular uptake visualization of Alexa Fluor 488 tagged PSA-TMC
coated with Texas Red labeled decoy ODNs in SW982 synovial sarcoma
cells. Cells were incubated with tagged particles for 45 minutes at 37 °C,
and then imaged using an inverted fluorescent microscope. When
administered alone, decoy ODN do not register a large signal. However,
when delivered using the PSA-TMC carrier system, both red and green
signals are clearly seen. NP PSA-TMC nanoparticles, ODN oligonucleotide
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respectively. In addition to other roles in the inflam-
matory response, IL-6 and IL-8 play a role in stimula-
tion of vascular endothelial growth factor (VEGF), a
growth factor linked to production of blood vessels
[42]. The newly and hence typically rapidly formed
blood vessels have larger pore sizes between the
endothelial barrier than normal blood vessels, which
can be exploited for drug delivery via the enhanced
permeation and retention (EPR) effect [43]. Colloidal
carrier systems between 100 and 200 nm can pas-
sively accumulate in areas associated with blood ves-
sels with larger, leaky pores in the endothelial barrier;
thus, the EPR effect is a means of passive targeting
[30]. While RA pathology does not exhibit the reten-
tion aspect of this phenomenon, the enhanced perme-
ation appears to be great enough to act as a passive
targeting mechanism [44, 45].
As NF-κB has a well-established involvement in RA,
the transcription factor is an enticing target for drug
candidates. However, as demonstrated here and in pre-
vious studies, administration of decoy ODNs alone re-
sults in low efficacy and delivery with many available
reagents results in high degrees of cytotoxicity [24]. As
shown in Fig. 6, the use of PSA–TMC as a carrier sys-
tem for decoy ODNs drastically increases the presence
of the decoy within the cell, proving an increased
amount of therapeutic at the site of action while main-
taining cell health. With the use of the PSA-TMC carrier
system, a lower amount of ODN can be administered,
thereby decreasing potential adverse effects from the de-
coys themselves.
We have previously established increased anti-
inflammatory bioactivity of an NF-κB decoy when ad-
ministered via NP in comparison with administration
without a delivery vehicle in a CF in vitro model [24].
Likewise, in the current study, decoy ODN efficacy
was increased when administered via PSA–TMC to
primary and cell line in vitro models of RA. SW982
cells yielded significantly decreased levels of IL-6 in
response to treatment with NP-ODN-MTX at 24 and
48 hours and in response to NP-MTX at 48 hours
only. As primary cells are isolated from different
individuals, it is not unexpected to observe increased
variability among cytokine expression and secretion
when compared with cell line groups [46], as seen
here.
With regards to the effect of MTX on cytokine
modulation, there have been conflicting reports. Early
reports by Loetscher et al. claimed that MTX is inef-
fective at mediating IL-8 production in RA [47], while
Kraan et al. reported decreased IL-8 in synovial fluid
after MTX treatment [48]. Similarly, Nishina et al.
[49] recently reported MTX effectively reduced IL-6
plasma levels in RA patients, while Inoue et al. [50]
claimed that MTX did not have an inhibitory effect
on IL-6 production by RA synovial cells. Previous
studies conducted by our group found MTX delivery
alone to be inconsistent, providing further evidence
that the therapeutic effects of MTX may not be man-
ifested in changes in the cytokine milieu [25].
The cytokine results portrayed in Figs. 2, 3, 4 and 5
in response to MTX alone are reflective of the variable
response observed among RA patients. In addition to
unpredictable efficacy, MTX is associated with a num-
ber of severe, dose-dependent side effects, limiting the
tolerable dosage level. Several reports advocate for
combination therapy of DMARDs, particularly MTX,
with biologic therapies. For example, a report by
Goekoop-Ruiterman et al. [51] claimed increased clin-
ical improvement in early stages of diseases progression
with combination therapies. Likewise, claims of in-
creased efficacy of low-dose MTX combined with
alternative therapies, such as phosphodiesterase type 3
inhibitor cilostazol, have also been reported [52]. In-
deed, primary RASF cells showed a significant response
in IL-6 levels to treatment with NP-ODN-MTX and
NP-ODN, but not NP-MTX or MTX alone. The pri-
mary cell model also resulted in a significant reduction
of IL-8 in response to NP-ODN, NP-MTX, NP-ODN-
MTX, and MTX in comparison with an untreated
control; however, only NP-ODN-MTX resulted in a sig-
nificant decrease in comparison with just ODN delivery
alone. These results suggest that decoy ODN has the
ability to act alone, as well as to enhance efficacy of
DMARD MTX when delivered in combination. NP pro-
vide a delivery vehicle to safely enhance cellular uptake
of ODN, as well as encapsulate and carry MTX to the
required site of action.
Conclusion
In this study, we obtained results furthering our claim
that NP can be used to effectively deliver nucleic acid-
based drugs. Furthermore, we showed the combination
of NF-κB decoy ODN and DMARD MTX resulted in
reduction in inflammatory cytokines in both cell line
and primary RASF models of RA in more instances
than treatment with either therapy individually. To our
knowledge, this is the first report investigating combin-
ation therapy of MTX with a decoy ODN. While NP
have been used to administer both MTX and ODN sep-
arately in previous studies, this is the first time we have
attempted to combine these two therapies and report
successful modulation of inflammatory proteins in RA
in vitro models [24, 25]. Incorporating in vivo testing is
necessary to determine both safety and efficacy of
PSA–TMC loaded with ODN and MTX, but this pre-
liminary in vitro investigation provides strong evidence
to support future studies.
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